期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 205, 期 4, 页码 981-992出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20071854
关键词
-
资金
- NCI NIH HHS [CA006927, P30 CA006927] Funding Source: Medline
- NIAID NIH HHS [U54-AI57168, R01 AI065544, U54 AI057168, AI065544] Funding Source: Medline
Nonliving antiviral vaccines traditionally target proteins expressed at the surface of the virion with the hope of inducing neutralizing antibodies. Orthopoxviruses (OPVs), such as the human smallpox virus and the mouse-equivalent ectromelia virus (ECTV; an agent of mousepox), encode immune response modifiers (IRMs) that can increase virulence by decreasing the host immune response. We show that one of these IRMs, the type I interferon (IFN) binding protein ( bp) of ECTV, is essential for ECTV virulence and is a natural target of the antibody response. More strikingly, we demonstrate that immunization with recombinant type I IFN bp protects mice from lethal mousepox. Collectively, our experiments have important implications for our understanding of the role of IRMs in OPV virulence and of type I IFNs in OPV infections. Furthermore, our work provides proof of concept that effective antiviral vaccines can be made to prevent disease by targeting virulence factors as an alternative to the traditional approach that attempts to prevent infection by virus neutralization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据